Cargando…

Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1

BACKGROUND: Pirfenidone, an antifibrotic agent used for the treatment of idiopathic pulmonary fibrosis (IPF), functions by inhibiting myofibroblast differentiation, which is involved in transforming growth factor (TGF)-β1-induced IPF pathogenesis. However, unlike normal lung fibroblasts, the relatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, Jin, Togo, Shinsaku, Kadoya, Kotaro, Tulafu, Miniwan, Namba, Yukiko, Iwai, Moe, Watanabe, Junko, Nagahama, Kumi, Okabe, Takahiro, Hidayat, Moulid, Kodama, Yuzo, Kitamura, Hideya, Ogura, Takashi, Kitamura, Norikazu, Ikeo, Kazuho, Sasaki, Shinichi, Tominaga, Shigeru, Takahashi, Kazuhisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558902/ https://www.ncbi.nlm.nih.gov/pubmed/31185973 http://dx.doi.org/10.1186/s12931-019-1093-z

Ejemplares similares

Combination of glycopyrronium and indacaterol inhibits carbachol-induced ERK5 signal in fibrotic processes
por: Namba, Yukiko, et al.
Publicado: (2017)

Cancer‐associated fibroblast migration in non‐small cell lung cancers is modulated by increased integrin α11 expression
por: Iwai, Moe, et al.
Publicado: (2021)

Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients
por: Togo, Shinsaku, et al.
Publicado: (2017)

Role and New Insights of Pirfenidone in Fibrotic Diseases
por: Lopez-de la Mora, David Alejandro, et al.
Publicado: (2015)

Expression of thymidylate synthase predicts clinical outcomes of S-1-based chemotherapy in squamous cell lung cancer
por: Honma, Yuichiro, et al.
Publicado: (2017)

Maser: one-stop platform for NGS big data from analysis to visualization
por: Kinjo, Sonoko, et al.
Publicado: (2018)

Anti-fibrotic action of pirfenidone in Dupuytren’s disease-derived fibroblasts
por: Zhou, Chaoming, et al.
Publicado: (2016)

The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC
por: Marwitz, Sebastian, et al.
Publicado: (2020)

Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration
por: Ikeda, Satoshi, et al.
Publicado: (2022)

Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation
por: Ballester, Beatriz, et al.
Publicado: (2020)

Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone
por: Ma, Hsiao-Yen, et al.
Publicado: (2023)

Pressure overload induced right ventricular remodeling is not attenuated by the anti-fibrotic agent pirfenidone
por: Andersen, Stine, et al.
Publicado: (2019)

High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study
por: Sumiyoshi, Issei, et al.
Publicado: (2021)

The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts
por: Mediavilla-Varela, Melanie, et al.
Publicado: (2016)

Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
por: Molina-Molina, M., et al.
Publicado: (2018)

The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1
por: Xi, Yue, et al.
Publicado: (2021)

Pirfenidone Has Anti-fibrotic Effects in a Tissue-Engineered Model of Human Cardiac Fibrosis
por: Bracco Gartner, Thomas C. L., et al.
Publicado: (2022)

A Review of Pirfenidone as an Anti-Fibrotic in Idiopathic Pulmonary Fibrosis and Its Probable Role in Other Diseases
por: Shah, Parth V, et al.
Publicado: (2021)

Pirfenidone attenuates synovial fibrosis and postpones the progression of osteoarthritis by anti-fibrotic and anti-inflammatory properties in vivo and in vitro
por: Wei, Qilu, et al.
Publicado: (2021)

Design and rationale of a randomised, double-blind trial of the efficacy and safety of pirfenidone in patients with fibrotic hypersensitivity pneumonitis
por: Fernández Pérez, Evans R., et al.
Publicado: (2021)

Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis
por: Ikeda, Satoshi, et al.
Publicado: (2019)

Correction to: Pirfenidone attenuates synovial fibrosis and postpones the progression of osteoarthritis by anti-fibrotic and anti-inflammatory properties in vivo and in vitro
por: Wei, Qilu, et al.
Publicado: (2021)

Clinical features of squamous cell lung cancer with anaplastic lymphoma kinase (ALK)-rearrangement: a retrospective analysis and review
por: Watanabe, Junko, et al.
Publicado: (2018)

The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2: Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?
por: Ferrara, Francesco, et al.
Publicado: (2020)

Pirfenidone: is it tolerable?
por: Lara, Abigail, et al.
Publicado: (2016)

The new useful high-resolution computed tomography finding for diagnosing fibrotic hypersensitivity pneumonitis: “hexagonal pattern”: a single-center retrospective study
por: Okabayashi, Hiroko, et al.
Publicado: (2022)

Pirfenidone, an Anti-Fibrotic Drug, Suppresses the Growth of Human Prostate Cancer Cells by Inducing G(1) Cell Cycle Arrest
por: Ishii, Kenichiro, et al.
Publicado: (2019)

The in vitro anti-fibrotic effect of Pirfenidone on human pterygium fibroblasts is associated with down-regulation of autocrine TGF-β and MMP-1
por: Tao, Yijin, et al.
Publicado: (2020)

The reduction of miR146b-5p in monocytes and T cells could contribute to the immunopathogenesis of hepatitis C virus infection
por: Kondo, Yasuteru, et al.
Publicado: (2019)

Lack of interleukin‐6 in the tumor microenvironment augments type‐1 immunity and increases the efficacy of cancer immunotherapy
por: Ohno, Yosuke, et al.
Publicado: (2017)

Inhibition of poly (adenosine diphosphate-ribose) polymerase attenuates lung-kidney crosstalk induced by intratracheal lipopolysaccharide instillation in rats
por: Khin Hnin Si, May, et al.
Publicado: (2013)

Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients
por: Feng, Haoshen, et al.
Publicado: (2020)

Pirfenidone-induced Eosinophilic Pleurisy
por: Hase, Isano, et al.
Publicado: (2017)

Biphasic Effect of Pirfenidone on Angiogenesis
por: Gan, Donghao, et al.
Publicado: (2022)

Effects of atrial natriuretic peptide on inter-organ crosstalk among the kidney, lung, and heart in a rat model of renal ischemia-reperfusion injury
por: Mitaka, Chieko, et al.
Publicado: (2014)

Inhibition of Ureteral Stricture by Pirfenidone-Loaded Nanoparticle-Coated Ureteral Stents with Slow-Release Pirfenidone
por: Jiang, Zhaosheng, et al.
Publicado: (2022)

Gene-by-Gene or Localized Dosage Compensation on the Neo-X Chromosome in Drosophila miranda
por: Nozawa, Masafumi, et al.
Publicado: (2018)

The synergetic effect of Imipenem-clarithromycin combination in the Mycobacteroides abscessus complex
por: Takei, Satomi, et al.
Publicado: (2020)

HJURP is involved in the expansion of centromeric chromatin
por: Perpelescu, Marinela, et al.
Publicado: (2015)

Constitutive centromere-associated network controls centromere drift in vertebrate cells
por: Hori, Tetsuya, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cqr9grbj77s252ehg0bduu0h31